Apyx Medical Corp
Business
Apyx Medical Corporation is a surgical aesthetics company that designs, develops, and manufactures energy-based surgical devices for cosmetic and hospital surgical markets. Its core products include Renuvion and J-Plasma (helium plasma technology systems) and the AYON Body Contouring System, all delivered as electrosurgical generators, handpieces, and helium gas supplies. The company operates two reportable segments: Surgical Aesthetics (focused on the cosmetic surgery market in the U.S. via direct sales force and international distributors) and OEM (contract manufacturing of electrosurgical equipment for other medical device manufacturers). It manufactures primarily in Clearwater, Florida and Sofia, Bulgaria.
Summary from 10-K filed 2026-03-10
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Sales, net | 53 | 48 | 52 | — | — | |
| Cost of sales | 20 | 19 | 19 | 15 | 15 | |
| Gross profit | 33 | 29 | 34 | 29 | 34 | |
| Research and development | 3 | 5 | 5 | 5 | 4 | |
| Professional services | 6 | 7 | 7 | 9 | 8 | |
| Salaries and related costs | 14 | 17 | 19 | — | — | |
| Selling, general and administrative | 16 | 19 | 22 | 20 | 19 | |
| Total other costs and expenses | 39 | 48 | 54 | 53 | 48 | |
| Loss from operations | −6 | −19 | −17 | −24 | −14 | |
| Interest income | 1 | 2 | 921,000 | — | — | |
| Interest expense | −6 | −6 | −2 | — | — | |
| Other Operating Income (Expense), Net | 92,000 | −161,000 | 622,000 | 509,000 | −373,000 | |
| Total other expense, net | −4 | −4 | −4 | — | — | |
| Loss before income taxes | −11 | −23 | −21 | −23 | −15 | |
| Income tax expense | 270,000 | 252,000 | −2 | 367,000 | 380,000 | |
| Net loss | −11 | −24 | −19 | −23 | −15 | |
| Net loss attributable to non-controlling interest | 106,000 | −96,000 | −137,000 | −94,000 | −28,000 | |
| Net loss attributable to stockholders | −11 | −23 | −19 | −23 | −15 | |
| Basic and diluted (in dollars per share) | −0.27 | −0.66 | −0.54 | −0.67 | −0.44 | |
| Weighted average number of shares outstanding - basic and diluted (in shares) | 41 | 36 | 35 | 35 | 34 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 32 | 32 | 44 | 10 | 31 | |
| Trade accounts receivable, net of allowance of $1,020 and $1,000 | 17 | 15 | 14 | 11 | 13 | |
| Inventories, net of provision for obsolescence of $1,207 and $1,032 | 9 | 8 | 10 | 12 | 7 | |
| Prepaid expenses and other current assets | 1 | 2 | 3 | 3 | 2 | |
| Total current assets | 58 | 56 | 70 | 43 | 61 | |
| Property and equipment, net | 2 | 2 | 2 | 7 | 7 | |
| Operating lease right-of-use assets | 4 | 5 | 5 | 710,000 | 121,000 | |
| Finance lease right-of-use assets | 28,000 | 48,000 | 69,000 | 115,000 | 178,000 | |
| Other assets | 2 | 2 | 2 | 1 | 1 | |
| Total assets | 67 | 65 | 79 | 52 | 69 | |
| Accounts payable | 3 | 3 | 3 | 3 | 3 | |
| Accrued expenses and other current liabilities | 8 | 8 | 10 | 9 | — | |
| Current portion of operating lease liabilities | 407,000 | 335,000 | 347,000 | 216,000 | 122,000 | |
| Current portion of finance lease liabilities | 21,000 | 20,000 | 20,000 | 37,000 | 165,000 | |
| Total current liabilities | 12 | 11 | 13 | 12 | 13 | |
| Long-term debt, net of debt discounts and issuance costs | 35 | 34 | 33 | 0 | — | |
| Long-term operating lease liabilities | 4 | 4 | 5 | 470,000 | 0 | |
| Long-term finance lease liabilities | 12,000 | 33,000 | 53,000 | 73,000 | 18,000 | |
| Long-term contract liabilities | 1 | 1 | 1 | 1 | 1 | |
| Other liabilities | 347,000 | 259,000 | 198,000 | 181,000 | 166,000 | |
| Total liabilities | 52 | 51 | 52 | 14 | 15 | |
| Commitments and Contingencies (Note 17) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.001 par value; 75,000,000 shares authorized; 41,785,946 issued and outstanding as of December 31, 2025, and 37,793,886 issued and outstanding as of December 31, 2024 | 42,000 | 38,000 | 35,000 | 35,000 | 34,000 | |
| Additional paid-in capital | 104 | 92 | 81 | 73 | 66 | |
| Accumulated deficit | −89 | −78 | −54 | −36 | −13 | |
| Total stockholders equity | 15 | 14 | 27 | 38 | 54 | |
| Non-controlling interest | 291,000 | 125,000 | 221,000 | 211,000 | 305,000 | |
| Total equity | 15 | 14 | 27 | 38 | 54 | |
| Total liabilities and equity | 67 | 65 | 79 | 52 | 69 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 655,000 | 599,000 | 692,000 | 890,000 | 903,000 | |
| Provision for inventory obsolescence | 341,000 | 163,000 | 523,000 | — | — | |
| Provision for product warranties | 214,000 | 304,000 | 261,000 | — | 318,000 | |
| Loss on disposal of property and equipment | 19,000 | 13,000 | −3 | 75,000 | — | |
| Stock based compensation | 2 | 4 | 5 | 7 | 5 | |
| Allowance for credit losses | 423,000 | 396,000 | 279,000 | 315,000 | 128,000 | |
| Non-cash lease expense | 86,000 | 112,000 | 87,000 | — | — | |
| Non-cash interest expense | 956,000 | 1 | 545,000 | — | — | |
| Trade receivables | −1 | −2 | −4 | 2 | −5 | |
| Prepaid expenses and other assets | 237,000 | 857,000 | −188,000 | −523,000 | 1 | |
| Inventories | −1 | 2 | 1 | −6 | −3 | |
| Accounts payable | 355,000 | −63,000 | 25,000 | 67,000 | 1 | |
| Accrued and other liabilities | 209,000 | −2 | 276,000 | −1 | 3 | |
| Net cash used in operating activities | −8 | −18 | −5 | −20 | −10 | |
| Purchases of property and equipment | −1 | −722,000 | −533,000 | −1 | −723,000 | |
| Net cash used in investing activities | −1 | −722,000 | 7 | −1 | −723,000 | |
| Proceeds from stock option exercises | 488,000 | 0 | 86,000 | 365,000 | — | |
| Proceeds from capital raise | 9 | 7 | — | — | — | |
| Payment of direct incremental costs in capital raise | −248,000 | −224,000 | — | — | — | |
| Payment of debt costs | 0 | −11,000 | −3 | 0 | — | |
| Repayment of finance lease liabilities | −20,000 | −20,000 | −37,000 | −148,000 | — | |
| Contributions from non-controlling interest | 60,000 | 0 | 147,000 | 0 | 195,000 | |
| Net cash provided by financing activities | 10 | 7 | 32 | 217,000 | 24,000 | |
| Net change in cash and cash equivalents | −1,000 | −12 | 33 | −21 | −11 | |
| Effect of exchange rates on cash | −466,000 | 113,000 | — | — | — | |
| Interest | 5 | 5 | 2 | 15,000 | 10,000 | |
| Income taxes | 258,000 | 382,000 | 329,000 | — | — | |
| Fair value of common stock issued in debt amendment | 0 | 183,000 | 0 | — | — | |
| Transfer of machinery and equipment to inventory | 78,000 | 62,000 | 0 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Apyx Medical Corp's CIK number?
Apyx Medical Corp's SEC CIK number is 0000719135 (719135). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Apyx Medical Corp's SEC filings?
All of Apyx Medical Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Apyx Medical Corp last report earnings?
Apyx Medical Corp (APYX) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-015352). This is Apyx Medical Corp's most recent earnings filing of record — not a forecast of its next earnings date.
What is Apyx Medical Corp's most recent earnings 8-K?
Apyx Medical Corp's latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001437749-26-015352. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Apyx Medical Corp's latest earnings 8-K →
Look up any company's CIK number →